Enzolytics Stock Fundamentals
| ENZC Stock | USD 0.0009 0.0001 10.00% |
Enzolytics fundamentals help investors to digest information that contributes to Enzolytics' financial success or failures. It also enables traders to predict the movement of Enzolytics Pink Sheet. The fundamental analysis module provides a way to measure Enzolytics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Enzolytics pink sheet.
Enzolytics |
Enzolytics Company Shares Outstanding Analysis
Enzolytics' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Enzolytics Shares Outstanding | 2.44 B |
Most of Enzolytics' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Enzolytics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, Enzolytics has 2.44 B of shares currently outstending. This is much higher than that of the Healthcare sector and significantly higher than that of the Biotechnology industry. The shares outstanding for all United States stocks is significantly lower than that of the firm.
Enzolytics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Enzolytics's current stock value. Our valuation model uses many indicators to compare Enzolytics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Enzolytics competition to find correlations between indicators driving Enzolytics's intrinsic value. More Info.Enzolytics is one of the top stocks in return on asset category among its peers. It also is one of the top stocks in operating margin category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Enzolytics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Enzolytics' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Did you try this?
Run Portfolio Anywhere Now
Portfolio AnywhereTrack or share privately all of your investments from the convenience of any device |
| All Next | Launch Module |
Enzolytics Fundamentals
| Return On Asset | -7.05 | |||
| Operating Margin | (19.24) % | |||
| Current Valuation | 71.57 M | |||
| Shares Outstanding | 2.44 B | |||
| Price To Sales | 2,083 X | |||
| Revenue | 190 K | |||
| Gross Profit | 52.81 K | |||
| EBITDA | (886.77 K) | |||
| Net Income | (57.28 K) | |||
| Cash And Equivalents | 5.76 K | |||
| Total Debt | 233.12 K | |||
| Current Ratio | 0.01 X | |||
| Book Value Per Share | (0.63) X | |||
| Cash Flow From Operations | 4.89 M | |||
| Earnings Per Share | (4.76) X | |||
| Beta | -0.0481 | |||
| Market Capitalization | 125.65 M | |||
| Total Asset | 3.31 M | |||
| Net Asset | 3.31 M |
About Enzolytics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Enzolytics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Enzolytics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Enzolytics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Enzolytics, Inc., a drug development company, focuses to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. In addition, it has created a proprietary cell line that produces human monoclonal antibodies that target and neutralizes the HIV virus. Enzolytics operates under Biotechnology classification in the United States and is traded on OTC Exchange.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Enzolytics Pink Sheet
Enzolytics financial ratios help investors to determine whether Enzolytics Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Enzolytics with respect to the benefits of owning Enzolytics security.